Welcome to our dedicated page for Currenc Group news (Ticker: CURR), a resource for investors and traders seeking the latest updates and insights on Currenc Group stock.
Currenc Group Inc. (Nasdaq: CURR) regularly issues news updates that describe its activities as a fintech company focused on artificial intelligence (AI) solutions for financial institutions and digital remittance services. Its press releases cover both operational developments and corporate transactions, providing context for investors and other readers who follow CURR news.
Readers of this news feed can expect coverage of financial results, including quarterly and half-year reports that discuss Total Processing Value (TPV) through Tranglo, remittance revenues, airtime revenues, gross margin and EBITDA. These releases often include management commentary on remittance performance, shifts away from lower-margin airtime transfers and the expansion of AI initiatives.
Currenc’s news also highlights strategic and capital-structure actions. Examples in the supplied disclosures include a proposed reverse merger with Animoca Brands Corporation Limited, a definitive agreement to divest its 60% controlling interest in Tranglo to New Margin Holding Limited, convertible note financings with warrants, and a shares-for-debt transaction in which related party loans were converted into equity. Such announcements describe how the company intends to reshape its business mix, reduce debt and support AI, Web3 and digital assets initiatives.
Additional news items address governance and leadership, such as CEO transitions and amendments to executive employment agreements, as well as steps the company has taken to monitor potential naked short selling in its stock. Together, these categories of news provide insight into how Currenc presents its operational performance, strategic direction and shareholder-related actions over time.
Investors and observers who follow CURR news can use this stream of press releases to track updates on remittance operations, AI product development, proposed corporate combinations and financing arrangements as described directly by the company in its public communications.
CURE Pharmaceutical (OTC: CURR) announced that its skincare line, Seratopical Revolution, will be available at CVS starting Fall 2021. This partnership positions CURR for expansive market reach, targeting diverse customer needs with its innovative P3P complex, which enhances product efficacy without drying effects. CEO Nancy Duitch highlighted the brand's competitive edge through effective delivery systems and attractive packaging, alongside actress Nicole Kidman as a global ambassador. This development signifies an important milestone for CURR's growth strategy in the beauty industry.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced that Chief Business Officer Jonathan Berlent will present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17 at 7:00 a.m. EST. Berlent expressed pride in developing the company's psychedelic-based clinical pipeline, emphasizing the therapeutic potential of psychedelics for mental health disorders. The presentation will be accessible online for 90 days post-event. CURE is a leader in innovative drug delivery systems, operating from a state-of-the-art facility.
CURE Pharmaceutical Holding Corp. (OTC: CURR) has launched Seratopical Revolution, a new line of anti-aging beauty products developed in collaboration with global brand ambassador Nicole Kidman. The product line features 11 plant-based items designed to hydrate and rejuvenate skin, utilizing a proprietary delivery system that enhances absorption. Products are made in the U.S. and are affordably priced. The line includes items such as Loving Hands Essential Oil and Indulgence Brown Sugar Scrub, aiming to merge nature and science for effective skincare.
CURE Pharmaceutical Holding Corp. (OTC: CURR) will hold a webcast on May 27, 2021, at 5 p.m. EDT for its investors. CEO Rob Davidson and Nancy Duitch, CEO of The Sera Labs, will discuss the company's future positioning and current achievements. Shareholders are encouraged to submit questions before the event. The company operates a 25,000 sq. ft. FDA-registered manufacturing facility and is known for its CUREform™ drug delivery platform, which enhances drug efficacy and safety.
CURE Pharmaceutical (OTC: CURR) reported a significant Q1 2021 performance, with total revenue soaring over 400% year-on-year to $1.5 million. The company received FDA approval for its Investigational New Drug application for CUREfilm Blue™, targeting erectile dysfunction. Additionally, CURE is advancing clinical development of delivery vehicles for psychedelic compounds. A new line of Nutri-Strips™ vitamins was launched via its Sera Labs subsidiary. CURE also secured a $2.3 million payment from a resolved contract dispute in April 2021.
Summary not available.
Sera Labs, part of CURE Pharmaceutical (OTC: CURR), highlighted their participation in Collision 2021, a major tech conference, where CEO Nancy Duitch and actress Nicole Kidman discussed their collaboration and product innovation. The discussion emphasized their upcoming Q2 plant-based product launch and the importance of their proprietary PꝫP complex delivery systems in enhancing product efficacy. Duitch noted that the event generated substantial business momentum for Sera Labs, positioning them to set new standards in wellness and beauty.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced successful results from its Pharmacokinetics (PK)/bioequivalence studies, paving the way for further clinical development aimed at FDA approval. Utilizing its patented CUREfilm technology, the company is developing CUREfilm Blue™, an oral film for sildenafil citrate, enhancing patient experience by eliminating the need to swallow pills. CURE is excited to advance its partnering initiatives for commercialization following these promising results.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced that CEO Rob Davidson and Nancy Duitch, CEO of subsidiary Sera Labs, will present at the 2021 Sequire Cannabis Conference on April 20 at 2 p.m. EDT. They will highlight CURE’s patented drug delivery technology and its applications in cannabis and wellness products. The conference showcases over 15 companies, offering insights into investment opportunities in the cannabis sector. Attendees can access a video webcast of the presentation afterward.
Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), announced that actress Nicole Kidman will headline Collision 2021, North America’s leading tech conference. Kidman and Sera Labs CEO Nancy Duitch are set to discuss innovative delivery system technologies and proprietary methodologies in anti-aging products. The virtual conference from April 20-22, 2021, expects over 40,000 attendees from over 100 countries. Duitch emphasized the significance of this event, showcasing Sera Labs' commitment to leveraging science and technology in beauty and wellness.